Posts Tagged ‘Analysis’

Beckman Coulter, Inc. – SWOT Analysis – Market Research Reports On Aarkstore Enterprise

Monday, September 6th, 2010

Beckman Coulter, Inc. – SWOT Analysis company profile is the essential source for top-level company data and information. Beckman Coulter, Inc. – SWOT Analysis examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Beckman Coulter is engaged in the design, manufacture and marketing of biomedical testing instrument systems, tests and supplies. Its products are used in a range of applications, including medical research, clinical trials and drug discovery, and diagnostic laboratories in hospitals. The company primarily operates in the US, Europe and Asia Pacific regions. It is headquartered in Brea, California and employed about 11,800 people as of December 2009. The company recorded revenues of $3,260.6 million during the financial year (FY) ended December 2009, an increase of 5.2% over FY2008. The operating profit of the company was $231.2 million during FY2009, a decrease of 18.7% over FY2008. The net profit of the company was $147.1 million in FY2009, a decrease of 20.9% over FY2008.

Scope of the Report

- Provides all the crucial information on Beckman Coulter, Inc. required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting Beckman Coulter, Inc. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Beckman Coulter, Inc.
-Data is supplemented with details on Beckman Coulter, Inc. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Beckman Coulter, Inc.

Reasons to Purchase

- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available

Table of Contents :
SWOT COMPANY PROFILE: Beckman Coulter, Inc.
Key Facts: Beckman Coulter, Inc.
Company Overview: Beckman Coulter, Inc.
Business Description: Beckman Coulter, Inc.
Company History: Beckman Coulter, Inc.
Key Employees: Beckman Coulter, Inc.
Key Employee Biographies: Beckman Coulter, Inc.
Products & Services Listing: Beckman Coulter, Inc.
Products & Services Analysis: Beckman Coulter, Inc.
SWOT analysis: Beckman Coulter, Inc.
*Strengths: Beckman Coulter, Inc.
*Weaknesses: Beckman Coulter, Inc.
*Opportunities: Beckman Coulter, Inc.
*Threats: Beckman Coulter, Inc.
Company View: Beckman Coulter, Inc.
Top Competitors: Beckman Coulter, Inc.
Location and Subsidiary: Beckman Coulter, Inc.
*Head Office: Beckman Coulter, Inc.
*Other Locations and Subsidiaries: Beckman Coulter, Inc.

For more information please visit :

http://www.aarkstore.com/reports/Beckman-Coulter-Inc-SWOT-Analysis-23007.html

NRPGM Core facilities introduction – C1High Throughput Genome Analysis Core Facility

Saturday, September 4th, 2010


TheCore Facilities of NRPGM were set up based on the concept of resource integration and management centralization. The objective is to establish and maintain nationwide facilities to support basic research in the field of genomic medicine, providing high-priced, high-throughput, and state-of-the-art instruments, along with analytical and consulting services. The Cores also aim at developing multi-disciplinary technologies, encouraging collaborative research projects. In addition, the Cores take the responsibilities of propagating the novel technologies and educating nationwide researchers, through which the standard of research in genomic medicine will be increased. National Core Facilities is opened for use by researchers from academic and industrial institutions. The Core Facilities cover five major fields:A. Animal Models, Phenotyping, and Imaging Facilities for Diseases, B. Clinical Sample Banks for Genomics, C. Facilities for Basic Genomics, D. Facilities for Proteomics and Structural Genomics, and E. Facilities for Bioinformatics Each core performs five major activities: Service, Technological / R&D, Collaborative Research, Education, and Dissemination. C1High Throughput Genome Analysis Core Facility

NRPGM Core facilities – D3Core facility protein production and X-ray structural analysis

Monday, August 30th, 2010


TheCore Facilities of NRPGM were set up based on the concept of resource integration and management centralization. The objective is to establish and maintain nationwide facilities to support basic research in the field of genomic medicine, providing high-priced, high-throughput, and state-of-the-art instruments, along with analytical and consulting services. The Cores also aim at developing multi-disciplinary technologies, encouraging collaborative research projects. In addition, the Cores take the responsibilities of propagating the novel technologies and educating nationwide researchers, through which the standard of research in genomic medicine will be increased. National Core Facilities is opened for use by researchers from academic and industrial institutions. The Core Facilities cover five major fields:A. Animal Models, Phenotyping, and Imaging Facilities for Diseases, B. Clinical Sample Banks for Genomics, C. Facilities for Basic Genomics, D. Facilities for Proteomics and Structural Genomics, and E. Facilities for Bioinformatics Each core performs five major activities: Service, Technological / R&D, Collaborative Research, Education, and Dissemination. D3Core facility for protein production and X-ray structural analysis proteome.sinica.edu.tw

Analysis of the Global Medical Device Industry

Sunday, August 15th, 2010

In the new century, the global medical devices continue to enlarge the export market, even in case of financial crisis Silue, from January to November 2009, also reached 170.487 billion U.S. dollars. It is understood that, in 2007, the global medical device market volume reached 300 billion U.S. dollars, about 340 billion U.S. dollars of trade turnover and import trade of about 170 billion U.S. dollars, the market average growth rate of 7%, a huge market space.

    

    Affected by economic crisis, in 2009 the EU demand for imports fell by 4 percentage points, the main source of imports for the United States, Switzerland, China, Japan and other countries, of which China accounted for 8.35% market share, an increase of 2.1%. The remaining countries had declined.

    

    As the world’s second largest import market, U.S. demand fell by 5 percentage points in 2009 only reached 27.185 billion U.S. dollars. Because the markets are more scattered, not forming a unipolar situation, Mexico, Ireland, Germany, China, Japan, plays a major market, accounting for 60% import market. China is the fourth-largest import trade partner of the United States, 9% of the market share in 2009, imports from China increased by 5%.

    

    In 2009, the Japanese import demand essentially flat, down 0.59%, the U.S. accounted for the major market share as high as 36%. China is the third largest trading partner, imports from China increased by 7.26%, 9% market share.

    

    Data show that Europe, America and Japan is the world’s top three medical device market. Chinese market share of 7%, average annual growth rate of 18%, with a strong domestic market and the fast-growing export market, as the most growth potential of the country. Reached 22,666 in 2009, exports reached 12.24 billion U.S. dollars. Chinese Medicine & Health Products Import and Export Chamber of Commerce Cao Gang, deputy director of the Department said that in the future, China’s medical device industry, the correlation with the international market will be higher.

    Statistics show that in January 2010, China’s medical equipment exports amounted to 954.809 million U.S. dollars, up 10.73%, the highest calendar

Course Overview and Introduction: The Biologic Basis for Analysis of Genetic Variants

Thursday, August 12th, 2010


Thomas Pearson, MD, Ph.D. Professor, University of Rochester School of Medicine. Genetics for Epidemiologists: Applications of Human Genomics to Population Sciences, was a short course for investigators and trainees in the field of epidemiology and related population-based sciences. It was conducted by the National Human Genome Research Institute (NHGRI) on May 13-14, 2008 at Northwestern University in Chicago. The goal of Genetics for Epidemiologists (GFE) was to familiarize epidemiologists and population-based researchers with recent developments in the theory and methods of human genetics that might be applied to the study of the distribution, natural history and etiology of diseases in populations. The course consisted of eight one-hour lectures and focused on the interface between genetics and epidemiology. Emphasis was on the application of modern human genome analysis methodologies to studies of human populations through the design, conduct, analysis, and interpretation of studies which effectively answer the epidemiologic question of interest. GFE is co-sponsored by the Office of Population Genomics, NHGRI, and the Department of Preventive Medicine at Northwestern University’s Feinberg School of Medicine. These videocasts are provided as an educational tool for epidemiologic investigators interested in learning more about applying genomics to their work. More: www.genome.gov

Analysis of Genetic Association Studies

Sunday, August 8th, 2010


Teri Manolio, MD, Ph.D. Director, Office of Population Genomics, NHGRI. Genetics for Epidemiologists: Applications of Human Genomics to Population Sciences, was a short course for investigators and trainees in the field of epidemiology and related population-based sciences. It was conducted by the National Human Genome Research Institute (NHGRI) on May 13-14, 2008 at Northwestern University in Chicago. The goal of Genetics for Epidemiologists (GFE) was to familiarize epidemiologists and population-based researchers with recent developments in the theory and methods of human genetics that might be applied to the study of the distribution, natural history and etiology of diseases in populations. The course consisted of eight one-hour lectures and focused on the interface between genetics and epidemiology. Emphasis was on the application of modern human genome analysis methodologies to studies of human populations through the design, conduct, analysis, and interpretation of studies which effectively answer the epidemiologic question of interest. GFE is co-sponsored by the Office of Population Genomics, NHGRI, and the Department of Preventive Medicine at Northwestern University’s Feinberg School of Medicine. These videocasts are provided as an educational tool for epidemiologic investigators interested in learning more about applying genomics to their work. More: www.genome.gov

Medison Co., Ltd. Market Share Analysis of GlobalData now available at ReportsandReports

Monday, July 26th, 2010

Dallas, TX: ReportsandReports announce it Medison Co., Ltd. Market Share Analysis Market Research Report in its Store.

GlobalData’s medical devices report, “Medison Co., Ltd. Market Share Analysis” provides in-depth information on Medison’s market position in the global ultrasound systems market category. The report also provides data and information on the overall competitive landscape in the global ultrasound systems market. The report is supplemented with global corporate-level profile with information on the company’s business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

Global Company shares (in Revenues) information for the in the ultrasound systems market. Other Key players covered include Siemens Healthcare, GE Healthcare, Philips Healthcare, Toshiba Medical Systems, ESAOTE, SonoSite, and Hitachi Medical, among others.
Medison’s company shares (in Revenues) information in the global ultrasound systems market.
All the key data-points are for 2009 and cover all the key regions – North America, Europe, Asia Pacific (APAC), South Central America (SCA), and Middle East and Africa (MEA).
Global corporate-level profile with information on the company’s business segments, major products and services, competitors, and locations and subsidiaries.
Comprehensive coverage of the latest financial deals involving the company and its subsidiaries, if any – Mergers & Acquisitions (M&A), Asset Transactions, PE/VC, Equity Offerings, Debt Offerings, and Partnerships.

Reasons to buy

Develop sales and marketing strategies by identifying who-stands-where in the markets, Medison operates in.
Plan your competition strategies by identifying the company’s shares in the markets and geographic regions it operates in.
Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are involved in.
Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in the report.
Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not limited to Medison’s market positions.

1 Table of Contents

1.1 List of Tables 8
1.2 List of Figures 11

2 Introduction 14
2.1 What is This Report About? 14

3 In Vitro Diagnostics In Mexico 15
3.1 In Vitro Diagnostics, Market Segmentation 15
3.2 In Vitro Diagnostics, Mexico, Overall Revenue ($m), 2002-2016 16
3.3 In Vitro Diagnostics Market, Mexico, Revenue Mix ($m), 2009 18
3.4 In Vitro Diagnostics Market, Mexico, Category Contribution (%), 2009 19
3.5 In Vitro Diagnostics, Mexico, Company Share (2008-2009) 25

4 Clinical Chemistry In Mexico 26
4.1 Clinical Chemistry, Market Segmentation 26
4.2 Clinical Chemistry Market, Mexico, Revenue Mix ($m), 2009 27
4.3 Clinical Chemistry Market, Mexico, Category Contribution (%), 2009 28
4.4 Clinical Chemistry Overall Revenue (2002-2016) 29
4.4.1 Clinical Chemisty Analyzers Revenue (2002-2016) 33
4.4.2 Urine Analysis Revenue (2002-2016) 37
4.5 Clinical Chemistry Distribution Share (2008-2009) 41
4.6 Clinical Chemistry, Mexico, Company Share (2008-2009) 42

5 Genetic Testing In Mexico 44
5.1 Genetic Testing, Market Segmentation 44
5.2 Genetic Testing Market, Mexico, Revenue Mix ($m), 2009 45
5.3 Genetic Testing Market, Mexico, Category Contribution (%), 2009 46
5.4 Genetic Testing Overall Revenue (2002-2016) 47
5.5 Genetic Testing Distribution Share (2008-2009) 51
5.6 Genetic Testing, Mexico, Company Share (2008-2009) 52

6 Haematology In Mexico 54
6.1 Haematology, Market Segmentation 54
6.2 Haematology Market, Mexico, Revenue Mix ($m), 2009 55
6.3 Haematology Market, Mexico, Category Contribution (%), 2009 56
6.4 Haematology Overall Revenue (2002-2016) 57
6.4.1 Haematology Reagents Revenue (2002-2016) 61
6.4.2 Immunohaematology Revenue (2002-2016) 65
6.4.3 Haemostasis Revenue (2002-2016) 69
6.4.4 Haematology Rapid Tests Revenue (2002-2016) 73
6.4.5 Haematology Cell Counters Revenue (2002-2016) 75
6.5 Haematology Distribution Share (2008-2009) 78
6.6 Haematology, Mexico, Company Share (2008-2009) 79

7 Histology And Cytology In Mexico 81
7.1 Histology and Cytology, Market Segmentation 81
7.2 Histology and Cytology Market, Mexico, Revenue Mix ($m), 2009 82
7.3 Histology and Cytology Market, Mexico, Category Contribution (%), 2009 83
7.4 Histology And Cytology Overall Revenue (2002-2016) 84
7.4.1 Histology Revenue (2002-2016) 88
7.5 Histology and Cytology Distribution Share (2008-2009) 92
7.6 Histology And Cytology, Mexico, Company Share (2008-2009) 93

8 Immuno Chemistry In Mexico 95
8.1 Immuno Chemistry, Market Segmentation 95
8.2 Immuno Chemistry Market, Mexico, Revenue Mix ($m), 2009 96
8.3 Immuno Chemistry Market, Mexico, Category Contribution (%), 2009 97
8.4 Immuno Chemistry Overall Revenue (2002-2016) 98
8.4.1 Disease Specific Immunochemistry Revenue (2002-2016) 102
8.4.2 Drug Related Testing Revenue (2002-2016) 106
8.4.3 Endocrinology Tests Revenue (2002-2016) 109
8.4.4 Immunochemistry Analyzers Revenue (2002-2016) 112
8.5 Immuno Chemistry Distribution Share (2008-2009) 116
8.6 Immuno Chemistry, Mexico, Company Share (2008-2009) 117

9 Infectious Immunology In Mexico 119
9.1 Infectious Immunology, Market Segmentation 119
9.2 Infectious Immunology Market, Mexico, Revenue Mix ($m), 2009 120
9.3 Infectious Immunology Market, Mexico, Category Contribution (%), 2009 121
9.4 Infectious Immunology Overall Revenue (2002-2016) 122
9.5 Infectious Immunology Distribution Share (2008-2009) 126
9.6 Infectious Immunology, Mexico, Company Share (2008-2009) 127

10 Microbiology Culture In Mexico 129
10.1 Microbiology Culture, Market Segmentation 129
10.2 Microbiology Culture Market, Mexico, Revenue Mix ($m), 2009 130
10.3 Microbiology Culture Market, Mexico, Category Contribution (%), 2009 131
10.4 Microbiology Culture Overall Revenue (2002-2016) 132
10.4.1 Microbiology Analyzers Revenue (2002-2016) 136
10.5 Microbiology Culture Distribution Share (2008-2009) 140
10.6 Microbiology Culture, Mexico, Company Share (2008-2009) 141

11 Overview of Key Companies in Mexico In Vitro Diagnostics Market 142
11.1 F. Hoffmann-La Roche Ltd. 142
11.1.1 Company Overview 142
11.2 Share in the Mexico In Vitro Diagnostics Market 142
11.3 Abbott Laboratories 143
11.3.1 Company Overview 143
11.3.2 Share in the Mexico In Vitro Diagnostics Market 143
11.4 Siemens Healthcare 144
11.4.1 Company Overview 144
11.4.2 Share in the Mexico In Vitro Diagnostics Market 144
11.5 Beckman Coulter, Inc. 145
11.5.1 Company Overview 145
11.5.2 Share in the Mexico In Vitro Diagnostics Market 145
11.6 bioMerieux S.A. 146
11.6.1 Company Overview 146
11.6.2 Share in the Mexico In Vitro Diagnostics Market 146
11.7 Ortho-Clinical Diagnostics Inc. 147
11.7.1 Company Overview 147
11.7.2 Share in the Mexico In Vitro Diagnostics Market 147
11.8 Inverness Medical Innovations, Inc. 148
11.8.1 Company Overview 148
11.9 Becton, Dickinson and Company 148
11.9.1 Company Overview 148
11.10 Bio-Rad Laboratories, Inc. 149
11.10.1 Company Overview 149
11.11 Hologic, Inc. 149
11.11.1 Company Overview 149
11.12 OLYMPUS CORPORATION 150
11.12.1 Company Overview 150
11.13 Mindray Medical International Limited 150
11.13.1 Company Overview 150
11.14 Sysmex Corporation 151
11.14.1 Company Overview 151
11.15 Ventana Medical Systems, Inc. 151
11.15.1 Company Overview 151
11.16 DiaSorin S.p.A 151
11.16.1 Company Overview 151
11.17 Qiagen N.V. 152
11.17.1 Company Overview 152
11.18 Gen-Probe Incorporated 152
11.18.1 Company Overview 152
11.19 Phadia AB 152
11.19.1 Company Overview 152

12 In Vitro Diagnostics Market Pipeline Products 153
12.1 Clinical Chemisty Market Pipeline Products 153
12.2 Immuno Chemistry Market Pipeline Products 155
12.3 Haematology Market Pipeline Products 156
12.4 Infectious Immunology Market Pipeline Products 157
12.5 Microbiology Culture Market Pipeline Products 159
12.6 Histology and Cytology Market Pipeline Products 160
12.7 Genetic Testing Market Pipeline Products 161

13 Financial Deals Landscape 163
13.1 Partnerships 163
13.1.1 QIAGEN Enters Into Distribution Agreement With Celera 163
13.1.2 Sequenom Enters Into Licensing Agreement With Optherion 164
13.1.3 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University 165
13.1.4 OraSure Technologies Enters Into An Agreement With Roche Diagnostics 166
13.1.5 Inverness Medical Innovations Enters Into Distribution Agreement With Epocal 167

14 Appendix 168
14.1 Definitions of Markets Covered in the Report 169
14.1.1 In Vitro Diagnostics 169
14.2 Research Methodology 176
14.3 Secondary Research 177
14.4 Primary Research 177
14.5 Models 178
14.6 Forecasts 178
14.7 Expert Panels 178
14.8 GlobalData Consulting 178
14.9 Currency Conversion 179
14.10 Contact Us 179
14.11 Disclaimer 179

1.1 List of Tables

Table 1: Medison Co., Ltd., Key Information, 2009 8
Table 2: Diagnostic Imaging, Ultrasound Systems, Global, Company Share by Revenue ($m), 2009 15
Table 3: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Global, Revenue ($m) and Market Share (%), 2009 16
Table 4: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Asia-Pacific, Revenue ($m) and Market Share (%), 2009 17
Table 5: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Europe, Revenue ($m) and Market Share (%), 2009 18
Table 6: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Middle East and Africa, Revenue ($m) and Market Share (%), 2009 19
Table 7: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, North America, Revenue ($m) and Market Share (%), 2009 19
Table 8: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, South and Central America, Revenue ($m) and Market Share (%), 2009 19
Table 9: Medison Co., Ltd., Key Employees 20
Table 10: USD to Local Currency, Average Exchange Rate 2009 26

1.2 List of Figures

Figure 1: Diagnostic Imaging, Ultrasound Systems, Global, Company Share (%), 2009 14
Figure 2: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Global, Market Share (%), 2009 16
Figure 3: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Asia-Pacific, Market Share (%), 2009 17
Figure 4: Medison Co., Ltd., Diagnostic Imaging, Ultrasound Systems, Europe, Market Share (%), 2009 18
Figure 5: GlobalData Methodology 23

 

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

 

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

 

<input id=”gwProxy” type=”hidden” /><input id=”jsProxy”>

Frbiz.com Reports Medical Devices Industry Analysis

Wednesday, July 14th, 2010

  The size of industrial cluster into three regions leading the trend for

  Medical equipment, Jiangsu Province, is characterized by small but complete. Products are mainly concentrated in the ophthalmology, orthopedics, surgical instruments, disposable medical equipment supplies and so on. Medical equipment such as a one-time items, Jiangsu, accounting for almost more than half of the national market, there are a number of products into the international market. Routine needs of the hospital medical equipment, generally can be found in Jiangsu Province. “April 26, the 55th China International Medical Equipment Fair Spring-cum-second session of the China International Medical Equipment Design and Manufacturing Technology Exhibition held in Shenzhen, the Shenzhen International Exhibition Hall in the noisy, is attending the medical device, Jiangsu Province, Cheng, general manager of industrial companies and in detail to the reporters said.

 

    ”Jiangsu affiliated with Shanghai as the center of the Yangtze River Delta. In fact not only in Jiangsu, high-quality disposable medical equipment supplies and consumables sales at home and abroad, but also the Yangtze River Delta region, a feature of the medical device industry.” State 863 Project “of China’s modernization Digital the core and key technologies of medical equipment, “Task Force Leader, Beijing Institute of Technology Professor Wu Chi-Yao says.

 

    Wu Chi-yao said that, in fact, as China’s medical device industries, the country has formed a number of medical device manufacturing industry, gathering area and the development zone; Pearl River Delta, Yangtze River Delta and Beijing-Tianjin-Bohai Bay region as the three local the three major medical device industry cluster areas. According to incomplete statistics, the three major regional medical equipment output value of the sum of the sum of their sales account for more than 80% of the national total. Because of different conditions inherent in these three industrial agglomerations also showing a significant local characteristics.

 

    The Pearl River Delta path of internationalization

 

    Speaking of Shenzhen’s scientific and technological innovation, people do not lose sight of some medical equipment manufacturing enterprises, such as Mindray Bio-Medical Electronics Co., Ltd., Anke High-tech Co., Ltd. and so on. Most of these companies are large-scale production of high-tech medical equipment-based.

 

    In fact, in Shenzhen as the center of the Pearl River Delta (including Zhuhai, Guangzhou and other places), research and development production of integrated high-tech medical equipment products are its strengths, the main products include monitoring equipment, ultrasound, MRI and other medical imaging equipment, and gamma ma knife, X knife stereotactic radiotherapy equipment and other large tumor hyperthermia equipment, a direct reflection of the modern medical equipment of the new technology. Shenzhen rapid development of medical equipment exports, the output value of more than 30% annually. Shenzhen Association of Medical Device Tao Duchun said that in 2005 alone, the medical device industry in Shenzhen’s GDP reached 5.338 billion yuan, up 30.2%; exports 377 million U.S. dollars, an increase of 72.9%. Wu Chi-yao said: “This area of international exchange, trade, cooperation dynamic. Products based on a globally integrated market, attach importance to the internationalization of production and operation management. Path of internationalization is an important feature of the region.”

 

    The most typical than Mindray. Mindray can be said that the representatives of China’s medical device industry, enterprise, at present their products to the Guardianship, clinical examination, ultrasound diagnosis of the three series of products with independent intellectual property rights. The company’s output value for three consecutive years of 50% of the rate of growth of output in 2005 reached 1.15 billion yuan output value in 2006 is expected to achieve 1.7 billion. Compared with other domestic enterprises, Mindray pay more attention to the development of global economic integration, at present its products in the international market and domestic market performance has been evenly divided.

 

    There is also a set of data is also very persuasive. To date, Shenzhen, 20% of companies take the initiative to implement an enterprise quality management system ISO third-party certification, and there are a considerable part of the product passed the European CE, U.S. FDA and other foreign products certification. The most influential in the international arena in Düsseldorf, Germany International Medical Equipment Fair (MEDICA), on 2004 in Shenzhen, 31 exhibiting companies, accounting for nearly 25% of participating enterprises.

 

    Obviously, the formation of this region with its unique policy environment, geographic location and the existing economic climate has a close relationship. Since the reform and opening up, Shenzhen has been playing a “window of China’s reform and opening up,” effect, the State providing relatively preferential development policies. Meanwhile, Shenzhen borders Hong Kong, foreign exchange facilities, easy to absorb the international advanced technology and experience. Coupled with the regional business developed, people’s thinking, active, making it the returned overseas students start the first leg. This is also precisely the ground for the development of sophisticated medical equipment to provide a reservoir of talent and technology.

 

    ”Shenzhen’s industrial advantages of electronics, computers, communications, mechanical and electrical integration of fields, and the development of modern medical equipment is an integrated high-tech achievements in these areas, resulting in intensification of advantages, coupled with the policy of Shenzhen, mechanisms, market factors such as incentives and cultivation, so that the medical device industry in Shenzhen to flourish. “commented one industry.

 

    Bohai Bay region, diagnosis and treatment technology, eye-catching

 

    On the scientific and technological strength, we can say that no place can match the National Beijing. Chinese Academy of Sciences, Tsinghua University and other top level of scientific research indicates that China’s scientific research institutes in Beijing. Is no exaggeration to say that in the medical device industry, the latest technology and personnel training strengths are in Beijing, but because of Beijing than Shanghai industrial base, industrial base than in Shenzhen, scientific and technological achievements in the industry to reflect on their ability to do so out of proportion with the R & D . Reporter in the Pavilion “Beijing group” also found an interview in Beijing despite the number of participating companies a lot, but few products, and more by virtue of the political center of Beijing’s unique status of the agent of foreign products. However, Miss Chi-yao said that as the adjustment of government policies, as well as changes in people’s attitudes in recent years in Beijing as the center ring of Bo in the Gulf region (including Tianjin, Liaoning, Shandong), the momentum of rapid development of medical devices, including a DR, MRI, digital ultrasound, accelerator, computer navigation and positioning medical equipment and respiratory anesthesia machine, including the number of diagnosis and treatment equipment manufacturing enterprise group is taking shape.

 

    ”A group of SMEs in the region, the rapid rise of concern. These enterprises to set up a few years time, but production has been close to or more than 100 million yuan. They are with the Government’s concern, as well as scientific and technological capabilities inherent in even more inclined to digital medical equipment in this area, although the market is not yet demonstrated the power of a very prominent and powerful, but the momentum strong, the potential should not be overlooked. ”

 

    Wu Chi-yao, told reporters that cited two examples. Beijing Tian Hui China Digital Technology Co., Ltd. was incorporated in 2001, began in 2003 to launch its own product. When the low-end analog ultrasound overwhelming, the company’s high-end technology development using conventional equipment, to develop a class of digital black and white ultrasound products. Good technical course presents a good market, it is learned that the company’s products in medical institutions, one-year bid procurement reached more than 7,000 yuan. Present its output has reached billion.

 

    Similarly there are Beijing Institute of Tece magnetic. MRI magnetic field on the market more than a strong following in the 0.35T, which are developed with the use of the original innovative content and technology with independent intellectual property rights, made a 0.5T-level permanent magnet, the field strength magnets to achieve the same at home and abroad The maximum magnetic field level. This not only shows that China has permanent MRI magnet to the world advanced level in the field of a big leap forward, but also to enable local enterprises in the fierce market competition to get a certain amount of right to speak. Some experts said the MRI market size in China in 2010 will reach 1,000 billion yuan, the industrialization of the technology, once achieved, will have a very broad market space.

 

    However, Wu Chi-yao stressed: “pay attention to how science and technology advantages into economic advantages, and actively promoting innovation and transformation platform for the construction of Beijing’s recent developments in the medical device industry, an issue requiring attention.”

 

    Outstanding performance in small and medium enterprises in Yangtze River Delta

 

    Speaking in Shanghai, China Society of Biomedical Engineering Professor Yang Guozhong executive director of deep emotion. He said the planned economy era, as has a solid industrial base, whether products or technologies, Shanghai is China’s medical device industry leader. However, due to industrial operation, and the concept of the idea of flexibility than in Shenzhen, the market economy, Shanghai’s leading position in the industry declined. However, in the original sound industrial base, rapid development of private enterprises, as well as Jiangsu developed organic chemical industry, led by the Shanghai-centered Yangtze River Delta region (including Jiangsu, Zhejiang) became China’s medical equipment, one of the three major industry groups.

 

    Wu Chi-yao said that the region is characterized by the rapid industrial development, small and medium enterprises active obvious regional characteristics. “In the past this area is mainly producing high-tech products, and now because of back with Jiangsu, Zhejiang, mainly the production of disposable medical equipment and supplies mainly. In addition, there are ophthalmic devices such as Suzhou, Wuxi, Medical Ultrasound, Nanjing, microwave, radio-frequency tumor hyperthermia, Ningbo and Shanghai’s overall strength MRI, are relatively more prominent. ”

 

    Jiangsu representation of certain medical equipment. Cheng-zhong, and says that in the medical equipment “small and complete” feature under the Jiangsu did not like MRI, CT and other large medical equipment; X-ray machine manufacturers in Jiangsu particularly large, but does not exceed 500 mA . But in the entire process of medical devices, Jiangsu, when the fast-growing number of private enterprises in southern Jiangsu. Although the technical content of these products is not high, but the internationalization of production and sales, it has a good reputation abroad.

 

    Headquarters in Shanghai, Zhejiang, Wenzhou, Candeley Group is specialized in production of disposable medical devices, research and development, sales business, to obtain import and export rights in 1998 after its products are exported to the United States, Britain, Germany and other countries. In 2005, the company’s output of 7.6 billion yuan, exports accounted for 60% to 70%. Wu Chi-yao, told this reporter that the company’s products although the technical content is not high enough, it has fully realized the “internationalization”, that is, in accordance with international standards of production, products, through international-related certification, to achieve the international market, direct sales. “Leaving aside the great products, so they took a small needle, its production are used in the most advanced production lines, the production process all the modernization.”

 

    For the future development trend of the region, stakeholders said that at present the development of Shanghai Medical Device Industry Strategy Research is being carried out, at present not yet available. However, Wu Chi-yao pointed out that Shanghai has emerged a group of high-tech products in emerging companies. Such as minimally invasive medical devices (Shanghai) Co., Ltd. is the first company specializing in minimally invasive interventional medical device R & D and production enterprises, its vascular stents and catheter products already account for a large share of the domestic market and exported to Europe, the United States, Japanese national, is an international market, fast-rising Chinese brands. Can be expected that, with this trend, the future of the region, the proportion of disposable supplies will be less than the production.

BioMEMS and Biomedical Nanotechnology: VI: Biomedical & Biological Nanotechnology. V2: Micro/Nano Technology for Genomics and Proteomics. V3: Therapeutic … Sensing, Processing and Analysis

Monday, July 12th, 2010

Product Description
The frontiers of microtechnology and nanotechnology are changing the face of medicine through the efforts of researchers to build biomedical microelectromechanical systems, or bioMEMS – tiny working machines so small, they measure only a few millionths of a meter across.  BIOMEMS AND BIOMEDICAL NANOTECHNOLOGY, edited by Mauro Ferrari, comprises the first comprehensive reference devoted to all aspects of research in the diagnostic and therapeutic applications of Mi… More >> BioMEMS and Biomedical Nanotechnology: VI: Biomedical & Biological Nanotechnology. V2: Micro/Nano Technology for Genomics and Proteomics. V3: Therapeutic … Sensing, Processing and Analysis

Medical Devices Industry Analysis

Saturday, July 10th, 2010

  The size of industrial cluster into three regions leading the trend for

  Medical equipment, Jiangsu Province, is characterized by small but complete. Products are mainly concentrated in the ophthalmology, orthopedics, surgical instruments, disposable medical equipment supplies and so on. Medical equipment such as a one-time items, Jiangsu, accounting for almost more than half of the national market, there are a number of products into the international market. Routine needs of the hospital medical equipment, generally can be found in Jiangsu Province. “April 26, the 55th China International Medical Equipment Fair Spring-cum-second session of the China International Medical Equipment Design and Manufacturing Technology Exhibition held in Shenzhen, the Shenzhen International Exhibition Hall in the noisy, is attending the medical device, Jiangsu Province, Cheng, general manager of industrial companies and in detail to the reporters said.

 

    ”Jiangsu affiliated with Shanghai as the center of the Yangtze River Delta. In fact not only in Jiangsu, high-quality disposable medical equipment supplies and consumables sales at home and abroad, but also the Yangtze River Delta region, a feature of the medical device industry.” State 863 Project “of China’s modernization Digital the core and key technologies of medical equipment, “Task Force Leader, Beijing Institute of Technology Professor Wu Chi-Yao says.

 

    Wu Chi-yao said that, in fact, as China’s medical device industries, the country has formed a number of medical device manufacturing industry, gathering area and the development zone; Pearl River Delta, Yangtze River Delta and Beijing-Tianjin-Bohai Bay region as the three local the three major medical device industry cluster areas. According to incomplete statistics, the three major regional medical equipment output value of the sum of the sum of their sales account for more than 80% of the national total. Because of different conditions inherent in these three industrial agglomerations also showing a significant local characteristics.

 

    The Pearl River Delta path of internationalization

 

    Speaking of Shenzhen’s scientific and technological innovation, people do not lose sight of some medical equipment manufacturing enterprises, such as Mindray Bio-Medical Electronics Co., Ltd., Anke High-tech Co., Ltd. and so on. Most of these companies are large-scale production of high-tech medical equipment-based.

 

    In fact, in Shenzhen as the center of the Pearl River Delta (including Zhuhai, Guangzhou and other places), research and development production of integrated high-tech medical equipment products are its strengths, the main products include monitoring equipment, ultrasound, MRI and other medical imaging equipment, and gamma ma knife, X knife stereotactic radiotherapy equipment and other large tumor hyperthermia equipment, a direct reflection of the modern medical equipment of the new technology. Shenzhen rapid development of medical equipment exports, the output value of more than 30% annually. Shenzhen Association of Medical Device Tao Duchun said that in 2005 alone, the medical device industry in Shenzhen’s GDP reached 5.338 billion yuan, up 30.2%; exports 377 million U.S. dollars, an increase of 72.9%. Wu Chi-yao said: “This area of international exchange, trade, cooperation dynamic. Products based on a globally integrated market, attach importance to the internationalization of production and operation management. Path of internationalization is an important feature of the region.”

 

    The most typical than Mindray. Mindray can be said that the representatives of China’s medical device industry, enterprise, at present their products to the Guardianship, clinical examination, ultrasound diagnosis of the three series of products with independent intellectual property rights. The company’s output value for three consecutive years of 50% of the rate of growth of output in 2005 reached 1.15 billion yuan output value in 2006 is expected to achieve 1.7 billion. Compared with other domestic enterprises, Mindray pay more attention to the development of global economic integration, at present its products in the international market and domestic market performance has been evenly divided.

 

    There is also a set of data is also very persuasive. To date, Shenzhen, 20% of companies take the initiative to implement an enterprise quality management system ISO third-party certification, and there are a considerable part of the product passed the European CE, U.S. FDA and other foreign products certification. The most influential in the international arena in Düsseldorf, Germany International Medical Equipment Fair (MEDICA), on 2004 in Shenzhen, 31 exhibiting companies, accounting for nearly 25% of participating enterprises.

 

    Obviously, the formation of this region with its unique policy environment, geographic location and the existing economic climate has a close relationship. Since the reform and opening up, Shenzhen has been playing a “window of China’s reform and opening up,” effect, the State providing relatively preferential development policies. Meanwhile, Shenzhen borders Hong Kong, foreign exchange facilities, easy to absorb the international advanced technology and experience. Coupled with the regional business developed, people’s thinking, active, making it the returned overseas students start the first leg. This is also precisely the ground for the development of sophisticated medical equipment to provide a reservoir of talent and technology.

 

    ”Shenzhen’s industrial advantages of electronics, computers, communications, mechanical and electrical integration of fields, and the development of modern medical equipment is an integrated high-tech achievements in these areas, resulting in intensification of advantages, coupled with the policy of Shenzhen, mechanisms, market factors such as incentives and cultivation, so that the medical device industry in Shenzhen to flourish. “commented one industry.

 

    Bohai Bay region, diagnosis and treatment technology, eye-catching

 

    On the scientific and technological strength, we can say that no place can match the National Beijing. Chinese Academy of Sciences, Tsinghua University and other top level of scientific research indicates that China’s scientific research institutes in Beijing. Is no exaggeration to say that in the medical device industry, the latest technology and personnel training strengths are in Beijing, but because of Beijing than Shanghai industrial base, industrial base than in Shenzhen, scientific and technological achievements in the industry to reflect on their ability to do so out of proportion with the R & D . Reporter in the Pavilion “Beijing group” also found an interview in Beijing despite the number of participating companies a lot, but few products, and more by virtue of the political center of Beijing’s unique status of the agent of foreign products. However, Miss Chi-yao said that as the adjustment of government policies, as well as changes in people’s attitudes in recent years in Beijing as the center ring of Bo in the Gulf region (including Tianjin, Liaoning, Shandong), the momentum of rapid development of medical devices, including a DR, MRI, digital ultrasound, accelerator, computer navigation and positioning medical equipment and respiratory anesthesia machine, including the number of diagnosis and treatment equipment manufacturing enterprise group is taking shape.

 

    ”A group of SMEs in the region, the rapid rise of concern. These enterprises to set up a few years time, but production has been close to or more than 100 million yuan. They are with the Government’s concern, as well as scientific and technological capabilities inherent in even more inclined to digital medical equipment in this area, although the market is not yet demonstrated the power of a very prominent and powerful, but the momentum strong, the potential should not be overlooked. ”

 

    Wu Chi-yao, told reporters that cited two examples. Beijing Tian Hui China Digital Technology Co., Ltd. was incorporated in 2001, began in 2003 to launch its own product. When the low-end analog ultrasound overwhelming, the company’s high-end technology development using conventional equipment, to develop a class of digital black and white ultrasound products. Good technical course presents a good market, it is learned that the company’s products in medical institutions, one-year bid procurement reached more than 7,000 yuan. Present its output has reached billion.

 

    Similarly there are Beijing Institute of Tece magnetic. MRI magnetic field on the market more than a strong following in the 0.35T, which are developed with the use of the original innovative content and technology with independent intellectual property rights, made a 0.5T-level permanent magnet, the field strength magnets to achieve the same at home and abroad The maximum magnetic field level. This not only shows that China has permanent MRI magnet to the world advanced level in the field of a big leap forward, but also to enable local enterprises in the fierce market competition to get a certain amount of right to speak. Some experts said the MRI market size in China in 2010 will reach 1,000 billion yuan, the industrialization of the technology, once achieved, will have a very broad market space.

 

    However, Wu Chi-yao stressed: “pay attention to how science and technology advantages into economic advantages, and actively promoting innovation and transformation platform for the construction of Beijing’s recent developments in the medical device industry, an issue requiring attention.”

 

    Outstanding performance in small and medium enterprises in Yangtze River Delta

 

    Speaking in Shanghai, China Society of Biomedical Engineering Professor Yang Guozhong executive director of deep emotion. He said the planned economy era, as has a solid industrial base, whether products or technologies, Shanghai is China’s medical device industry leader. However, due to industrial operation, and the concept of the idea of flexibility than in Shenzhen, the market economy, Shanghai’s leading position in the industry declined. However, in the original sound industrial base, rapid development of private enterprises, as well as Jiangsu developed organic chemical industry, led by the Shanghai-centered Yangtze River Delta region (including Jiangsu, Zhejiang) became China’s medical equipment, one of the three major industry groups.

 

    Wu Chi-yao said that the region is characterized by the rapid industrial development, small and medium enterprises active obvious regional characteristics. “In the past this area is mainly producing high-tech products, and now because of back with Jiangsu, Zhejiang, mainly the production of disposable medical equipment and supplies mainly. In addition, there are ophthalmic devices such as Suzhou, Wuxi, Medical Ultrasound, Nanjing, microwave, radio-frequency tumor hyperthermia, Ningbo and Shanghai’s overall strength MRI, are relatively more prominent. ”

 

    Jiangsu representation of certain medical equipment. Cheng-zhong, and says that in the medical equipment “small and complete” feature under the Jiangsu did not like MRI, CT and other large medical equipment; X-ray machine manufacturers in Jiangsu particularly large, but does not exceed 500 mA . But in the entire process of medical devices, Jiangsu, when the fast-growing number of private enterprises in southern Jiangsu. Although the technical content of these products is not high, but the internationalization of production and sales, it has a good reputation abroad.

 

    Headquarters in Shanghai, Zhejiang, Wenzhou, Candeley Group is specialized in production of disposable medical devices, research and development, sales business, to obtain import and export rights in 1998 after its products are exported to the United States, Britain, Germany and other countries. In 2005, the company’s output of 7.6 billion yuan, exports accounted for 60% to 70%. Wu Chi-yao, told this reporter that the company’s products although the technical content is not high enough, it has fully realized the “internationalization”, that is, in accordance with international standards of production, products, through international-related certification, to achieve the international market, direct sales. “Leaving aside the great products, so they took a small needle, its production are used in the most advanced production lines, the production process all the modernization.”

 

    For the future development trend of the region, stakeholders said that at present the development of Shanghai Medical Device Industry Strategy Research is being carried out, at present not yet available. However, Wu Chi-yao pointed out that Shanghai has emerged a group of high-tech products in emerging companies. Such as minimally invasive medical devices (Shanghai) Co., Ltd. is the first company specializing in minimally invasive interventional medical device R & D and production enterprises, its vascular stents and catheter products already account for a large share of the domestic market and exported to Europe, the United States, Japanese national, is an international market, fast-rising Chinese brands. Can be expected that, with this trend, the future of the region, the proportion of disposable supplies will be less than the production.